Efficacy of different salvage regimens in progressive unresectable pediatric low-grade glioma

被引:2
|
作者
El-Hemaly, Ahmed [1 ,2 ]
Taha, Hala [3 ,4 ]
Refaat, Amal [5 ,6 ]
Adel, Fatima [7 ]
Elbeltagy, Mohamed [8 ,9 ]
Arafah, Omar [2 ,10 ]
机构
[1] Childrens Canc Hosp Egypt 57357, Dept Pediat Oncol, Cairo 11617, Egypt
[2] Cairo Univ, NCI, Dept Pediat Oncol, Cairo 11796, Egypt
[3] Cairo Univ, NCI, Dept Pathol, Cairo 11796, Egypt
[4] Childrens Canc Hosp Egypt 57357, Dept Pathol, Cairo 11617, Egypt
[5] Cairo Univ, NCI, Dept Radiodiag, Cairo 11796, Egypt
[6] Childrens Canc Hosp Egypt 57357, Dept Radiodiag, Cairo 11617, Egypt
[7] Childrens Canc Hosp Egypt 57357, Dept Res, Cairo 11617, Egypt
[8] Cairo Univ, Kasr Al Ainy Sch Med, Dept Neurosurg, Cairo 11796, Egypt
[9] Childrens Canc Hosp Egypt 57357, Dept Neurosurg, Cairo 11617, Egypt
[10] Cairo Univ, NCI, Dept Pediat Oncol, 1 Fom El Khaleeg St,Kasr El Aini Ave, Cairo 11796, Egypt
关键词
pediatric; progressive; unresectable; low-grade glioma; salvage chemotherapy; neurofibromatosis; 1; PHASE-II; CARBOPLATIN; CHILDREN; CHEMOTHERAPY; VINCRISTINE; RECURRENT; TUMORS;
D O I
10.3892/ol.2022.13527
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Multiple salvage chemotherapy regimens are used in progressive low-grade glioma (LGG), with no single regimen being more effective than any other. In the present study, different salvage therapies were compared with regard to the response rate, overall survival (OS) rate, event-free survival (EFS) rate and visual outcome in 70 patients with pediatric LGG. Age was found to significantly affect the EFS and OS rates (P<0.001). The visual outcome was the same between the three regimens. The 2-year EFS and OS rates of the vincristine/carboplatin, monthly carboplatin and weekly vinblastine regimens were 64.7 and 70.6%, 71.0 and 85.0%, and 56.0 and 62.7%, respectively (P=0.6 for EFS; P=0.56 for OS). Overall, the present study demonstrated that age had a significant impact on survival. The three salvage regimens used were equally effective with regard to the radiological response and visual outcome. However, further randomized controlled trials are required to detect the optimal salvage therapy.
引用
收藏
页数:8
相关论文
共 50 条
  • [1] Oral Vinorelbine in Progressive Unresectable Low-Grade Glioma
    Cappellano, A. M.
    Oliveira, M.
    Cavalheiro, S.
    Dastoli, P.
    Barbosa, D.
    Silva, F.
    Seixas, M. T.
    Saba-Silva, N.
    PEDIATRIC BLOOD & CANCER, 2020, 67 : S376 - S377
  • [2] ORAL VINORELBINE IN PROGRESSIVE UNRESECTABLE LOW-GRADE GLIOMA
    Cappellano, Andrea M.
    Oliveira, Milena R. S.
    Cavalheiro, Sergio
    Dastoli, Patricia
    Almeida, Daniela B.
    Silva, Frederico A.
    Alves, Maria Teresa S.
    Silva, Nasjla S.
    NEURO-ONCOLOGY, 2020, 22 : 383 - 383
  • [3] SINGLE AGENT VINORELBINE IN PEDIATRIC AND ADOLESCENT PATIENTS WITH PROGRESSIVE UNRESECTABLE LOW-GRADE GLIOMA
    Cappellano, A.
    Bouffet, E.
    Silva, F. A.
    Cavalheiro, S.
    Alves, M. T. S.
    Toledo, S.
    Dias, I.
    da Silva, N. S.
    PEDIATRIC BLOOD & CANCER, 2015, 62 : S273 - S273
  • [4] Vinorelbine in progressive unresectable low-grade glioma in children.
    Cappellano, A. M.
    Bouffet, E.
    Silva, F.
    Paiva, P.
    Alves, M. T. d. S.
    Cavalheiro, S.
    Silva, N. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [5] Use of bevacizumab as a single agent or in adjunct with traditional chemotherapy regimens in children with unresectable or progressive low-grade glioma
    Zhukova, Nataliya
    Rajagopal, Revathi
    Lam, Adrienne
    Coleman, Lee
    Shipman, Peter
    Walwyn, Thomas
    Williams, Molly
    Sullivan, Michael
    Campbell, Martin
    Bhatia, Kanika
    Gottardo, Nicholas G.
    Hanford, Jordan R.
    CANCER MEDICINE, 2019, 8 (01): : 40 - 50
  • [6] Trametinib for the treatment of recurrent/progressive pediatric low-grade glioma
    Neevika Manoharan
    Jungwhan Choi
    Christine Chordas
    Mary Ann Zimmerman
    Jacqueline Scully
    Jessica Clymer
    Mariella Filbin
    Nicole J. Ullrich
    Pratiti Bandopadhayay
    Susan N. Chi
    Kee Kiat Yeo
    Journal of Neuro-Oncology, 2020, 149 : 253 - 262
  • [7] Trametinib for the treatment of recurrent/progressive pediatric low-grade glioma
    Manoharan, Neevika
    Choi, Jungwhan
    Chordas, Christine
    Zimmerman, Mary Ann
    Scully, Jacqueline
    Clymer, Jessica
    Filbin, Mariella
    Ullrich, Nicole J.
    Bandopadhayay, Pratiti
    Chi, Susan N.
    Yeo, Kee Kiat
    JOURNAL OF NEURO-ONCOLOGY, 2020, 149 (02) : 253 - 262
  • [8] ORAL VINORELBINE IN PROGRESSIVE UNRESECTABLE LOW-GRADE GLIOMA: EXPERIENCE OF A SINGLE INSTITUTION
    Cappellano, Andrea
    Silveira, Cynthia M.
    Oliveira, Milena R. S.
    Cavalheiro, Sergio
    Dastoli, Patricia
    Alves, Maria Teresa S.
    Pereira, Gregorio
    Silva, Frederico A.
    Barbosa, Daniela
    Nasjla
    da Silva, Saba
    NEURO-ONCOLOGY, 2018, 20 : 116 - 116
  • [9] Response to trametinib treatment in progressive pediatric low-grade glioma patients
    Selt, Florian
    van Tilburg, Cornelis M.
    Bison, Brigitte
    Sievers, Philipp
    Harting, Inga
    Ecker, Jonas
    Pajtler, Kristian W.
    Sahm, Felix
    Bahr, Annabelle
    Simon, Michele
    Jones, David T. W.
    Well, Lennart
    Mautner, Victor-Felix
    Capper, David
    Hernaiz Driever, Pablo
    Gnekow, Astrid
    Pfister, Stefan M.
    Witt, Olaf
    Milde, Till
    JOURNAL OF NEURO-ONCOLOGY, 2020, 149 (03) : 499 - 510
  • [10] Response to trametinib treatment in progressive pediatric low-grade glioma patients
    Florian Selt
    Cornelis M. van Tilburg
    Brigitte Bison
    Philipp Sievers
    Inga Harting
    Jonas Ecker
    Kristian W. Pajtler
    Felix Sahm
    Annabelle Bahr
    Michèle Simon
    David T. W. Jones
    Lennart Well
    Victor-Felix Mautner
    David Capper
    Pablo Hernáiz Driever
    Astrid Gnekow
    Stefan M. Pfister
    Olaf Witt
    Till Milde
    Journal of Neuro-Oncology, 2020, 149 : 499 - 510